ES2183140T3 - Combinaciones, que tienen efectos inmunosupresores, que contienen un inhibidor de ciclooxigenasa-2 y un inhibidor de leucotrieno a4 hidrolasa. - Google Patents

Combinaciones, que tienen efectos inmunosupresores, que contienen un inhibidor de ciclooxigenasa-2 y un inhibidor de leucotrieno a4 hidrolasa.

Info

Publication number
ES2183140T3
ES2183140T3 ES97907545T ES97907545T ES2183140T3 ES 2183140 T3 ES2183140 T3 ES 2183140T3 ES 97907545 T ES97907545 T ES 97907545T ES 97907545 T ES97907545 T ES 97907545T ES 2183140 T3 ES2183140 T3 ES 2183140T3
Authority
ES
Spain
Prior art keywords
inhibitor
hydrolasses
leucotrene
cycloxygenasa
immunosuppressor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97907545T
Other languages
English (en)
Spanish (es)
Inventor
Susan A Gregory
Peter C Isakson
Gary Anderson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GD Searle LLC
Original Assignee
GD Searle LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GD Searle LLC filed Critical GD Searle LLC
Application granted granted Critical
Publication of ES2183140T3 publication Critical patent/ES2183140T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES97907545T 1996-02-13 1997-02-11 Combinaciones, que tienen efectos inmunosupresores, que contienen un inhibidor de ciclooxigenasa-2 y un inhibidor de leucotrieno a4 hidrolasa. Expired - Lifetime ES2183140T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60065596A 1996-02-13 1996-02-13

Publications (1)

Publication Number Publication Date
ES2183140T3 true ES2183140T3 (es) 2003-03-16

Family

ID=24404526

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97907545T Expired - Lifetime ES2183140T3 (es) 1996-02-13 1997-02-11 Combinaciones, que tienen efectos inmunosupresores, que contienen un inhibidor de ciclooxigenasa-2 y un inhibidor de leucotrieno a4 hidrolasa.

Country Status (11)

Country Link
US (3) US6407140B1 (https=)
EP (1) EP0880363B1 (https=)
JP (1) JP2001506574A (https=)
AT (1) ATE223732T1 (https=)
AU (1) AU1952597A (https=)
CA (1) CA2246336A1 (https=)
DE (1) DE69715382T2 (https=)
DK (1) DK0880363T3 (https=)
ES (1) ES2183140T3 (https=)
PT (1) PT880363E (https=)
WO (1) WO1997029774A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0880363T3 (da) * 1996-02-13 2003-01-20 Searle & Co Kombinationer der omfatter en cyclooxygenase-2 hæmmer samt en leukotrien A4 hydrolasehæmmer, som har immunsuppressive virkninger
JP2000504723A (ja) * 1996-02-13 2000-04-18 ジー．ディー．サール アンド カンパニー シクロオキシゲナーゼ―２阻害剤および５―リポキシゲナーゼ阻害剤投与の免疫抑制効果
SE9703693D0 (sv) * 1997-10-10 1997-10-10 Astra Pharma Prod Novel combination
EP1303265B1 (en) 2000-07-20 2007-07-11 Lauras AS Use of cox-2 inhibitors as immunostimulants in the treatment of hiv or aids
GB0112348D0 (en) * 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
AR038957A1 (es) 2001-08-15 2005-02-02 Pharmacia Corp Terapia de combinacion para el tratamiento del cancer
MXPA04003451A (es) 2001-10-09 2005-02-17 Dimensional Pharm Inc Difeniloxazoles substituidos, la sintesis de los mismos y el uso de los mismo como detectores fluorescencia.
WO2004019891A2 (en) * 2002-08-28 2004-03-11 Sangstat Medical Corporation Methods and compostions for immune tolerance
US7507531B2 (en) 2002-10-17 2009-03-24 Decode Genetics Chf. Use of 5-lipoxygenase activating protein (FLAP) gene to assess susceptibility for myocardial infarction
US7851486B2 (en) 2002-10-17 2010-12-14 Decode Genetics Ehf. Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment
EP1879875A1 (en) * 2005-04-22 2008-01-23 Wyeth Crystal forms opf {[(2r)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-1-benzofuran-2-yl]methyl}amine hydrochloride
AT502258B1 (de) * 2005-07-22 2007-09-15 Univ Wien Cox-i-inhibitorverbindungen
NL2000351C2 (nl) 2005-12-22 2007-09-11 Pfizer Prod Inc Estrogeen-modulatoren.
LT1976828T (lt) * 2005-12-29 2017-04-25 Celtaxsys, Inc. Diamino dariniai, kaip leukotrieno a4 hidrolazės inhibitoriai
AR069126A1 (es) 2007-10-31 2009-12-30 Janssen Pharmaceutica Nv Diaminas en puente o fusionadas sustituidas con arilo como moduladores de leucotrieno a4 hidrolasa
MY157597A (en) 2008-04-11 2016-06-30 Janssen Pharmaceutica Nv Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene a4 hydrolase
US8399465B2 (en) 2009-05-14 2013-03-19 Janssen Pharmaceutica Nv Compounds with two fused bicyclic heteroaryl moieties as modulators of leukotriene A4 hydrolase
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
AU2014249168B2 (en) 2013-03-12 2018-07-12 Celltaxis, Llc Methods of inhibiting leukotriene A4 hydrolase
BR112015022864A8 (pt) 2013-03-14 2019-11-26 Celtaxsys Inc composto, composição farmacêutica e uso dos mesmos
CA2906035A1 (en) 2013-03-14 2014-09-25 Celtaxsys, Inc. Inhibitors of leukotriene a4 hydrolase
WO2014152536A2 (en) 2013-03-14 2014-09-25 Celtaxsys, Inc. Inhibitors of leukotriene a4 hydrolase
NZ748641A (en) 2016-06-13 2020-04-24 Gilead Sciences Inc Fxr (nr1h4) modulating compounds
CA2968836C (en) 2016-06-13 2025-09-02 Gilead Sciences, Inc. FXR MODULATING COMPOUNDS (NR1H4)
SI4122464T1 (sl) 2017-03-28 2024-07-31 Gilead Sciences, Inc. Terapevtske kombinacije za zdravljenje bolezni jeter
ES3014615T3 (en) 2018-05-31 2025-04-23 Celltaxis Llc Method of reducing pulmonary exacerbations in respiratory disease patients
PT3911647T (pt) 2019-01-15 2024-03-04 Gilead Sciences Inc Composto de isoxazole como agonista de fxr e composições farmacêuticas que o contenham
JP2022519906A (ja) 2019-02-19 2022-03-25 ギリアード サイエンシーズ， インコーポレイテッド Ｆｘｒアゴニストの固体形態

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59196839A (ja) 1983-04-21 1984-11-08 Sankyo Co Ltd フエニル酢酸誘導体
US4873259A (en) 1987-06-10 1989-10-10 Abbott Laboratories Indole, benzofuran, benzothiophene containing lipoxygenase inhibiting compounds
US5242940A (en) 1987-05-29 1993-09-07 Ortho Pharmaceutical Corporation Pharmacologically active N-1 and C-5 heterocyclic pyrazoles and method for synthesizing the same
KR920003601B1 (ko) 1987-09-03 1992-05-04 유니버시티 어브 죠지아 리서취 화운데이션 인코포레이티드 점안 싸이클로스포린(cyclosporin)의 조성물
US5234950A (en) 1988-12-23 1993-08-10 Imperial Chemical Industries Plc Tetrahydrofuran derivatives
GB8927287D0 (en) 1988-12-23 1990-01-31 Ici Plc Cyclic ether derivatives
US5220059A (en) 1990-04-19 1993-06-15 Abbott Laboratories Lipoxygenase-inhibiting compounds derived from non-steroidal antiinflammatory carboxylic acids
ES2095325T3 (es) 1990-07-25 1997-02-16 Abbott Lab Derivados de acetileno con una actividad de inhibicion de la lipoxigenasa.
IE913655A1 (en) 1990-11-06 1992-05-22 Zeneca Ltd Synergistic agents
US5356898A (en) 1991-01-31 1994-10-18 Warner-Lambert Company Substituted 4,6-di-tertiary-butyl 5-hydroxy-pyrimidines
GB9215921D0 (en) 1992-07-27 1992-09-09 Wellcome Found Anti-inflammatory compounds
US5354865A (en) 1992-09-10 1994-10-11 Abbott Laboratories Phenylmethyl derivatives having lipoxygenase inhibitory activity
US5288751A (en) 1992-11-06 1994-02-22 Abbott Laboratories [(Substituted) phenyalkyl]furylalkynyl-and [substituted) phenyalkyl] thienylalkynyl-N-hydroxyurea inhibitors or leukotriene biosynthesis
US5604260A (en) 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
EP0679157B1 (en) 1993-01-15 1997-11-19 G.D. Searle & Co. Novel 3,4-diaryl thiophenes and analogs thereof having use as antiinflammatory agents
US5409944A (en) 1993-03-12 1995-04-25 Merck Frosst Canada, Inc. Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase
CA2161789A1 (en) 1993-05-13 1994-11-24 Jacques Yves Gauthier 2-substituted-3,4-diarylthiophene derivatives as inhibitors of cyclooxygenase
US5380738A (en) 1993-05-21 1995-01-10 Monsanto Company 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5298521A (en) 1993-08-30 1994-03-29 Ortho Pharmaceutical Corporation 1,5-diphenyl-3-pyrazolylalkyl-N-hydroxydithiocaramates, compositions and use
US5344991A (en) 1993-10-29 1994-09-06 G.D. Searle & Co. 1,2 diarylcyclopentenyl compounds for the treatment of inflammation
DE69422306T4 (de) 1993-11-30 2000-09-07 G.D. Searle & Co., Chicago Substituierte pyrazolyl-benzolsulfonamide zur behandlung von entzündungen
US5393790A (en) 1994-02-10 1995-02-28 G.D. Searle & Co. Substituted spiro compounds for the treatment of inflammation
US5486534A (en) * 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation
ES2247604T3 (es) 1995-06-12 2006-03-01 G.D. SEARLE & CO. Composiciones que comprenden un inhibidor de ciclooxigenasa-2 y un inhibidor de 5-lipoxigenasa.
US5700816A (en) * 1995-06-12 1997-12-23 Isakson; Peter C. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
ATE296114T1 (de) * 1996-02-13 2005-06-15 Searle & Co Zubereitungen, enthaltend einen cyclooxygenase-2- inhibitor und einen leukotrien-b4-rezeptor- antagonisten
DK0880363T3 (da) * 1996-02-13 2003-01-20 Searle & Co Kombinationer der omfatter en cyclooxygenase-2 hæmmer samt en leukotrien A4 hydrolasehæmmer, som har immunsuppressive virkninger

Also Published As

Publication number Publication date
EP0880363A1 (en) 1998-12-02
JP2001506574A (ja) 2001-05-22
CA2246336A1 (en) 1997-08-21
US20050043355A1 (en) 2005-02-24
DK0880363T3 (da) 2003-01-20
AU1952597A (en) 1997-09-02
WO1997029774A1 (en) 1997-08-21
US6407140B1 (en) 2002-06-18
US20030004191A1 (en) 2003-01-02
DE69715382D1 (de) 2002-10-17
DE69715382T2 (de) 2003-04-30
PT880363E (pt) 2002-12-31
EP0880363B1 (en) 2002-09-11
ATE223732T1 (de) 2002-09-15

Similar Documents

Publication Publication Date Title
ES2183140T3 (es) Combinaciones, que tienen efectos inmunosupresores, que contienen un inhibidor de ciclooxigenasa-2 y un inhibidor de leucotrieno a4 hidrolasa.
ES2177482T1 (es) Preparacion mejorada de tebaina y oripavina.
ES2162937T3 (es) Preparado combinado para su aplicacion en enfermedades inmunologicas.
DE69526206D1 (de) Verwendung von interleukin-12 fuer die verhinderung von transplantat gegen empfaengerkrankheit
DE69129332D1 (de) Behandlung von organtransplantatsabstossung
ES2154299T3 (es) Metodos para la regulacion de la motilidad gastrointestinal.
ECSP941135A (es) Antagonistas triciclicos de vasopresina de benzacepina
BG102690A (en) Il-8 receptor antagonists
BR9814040A (pt) Agudo no pulmão com fibrose com antagonistas de avb6
HU896748D0 (en) Biocid compositions
MX9306960A (es) Composiciones de extracto de corteza de roble, compositiones sinteticasrelacionadas, y metodo para su utilizacion.
DK0517797T3 (da) Anvendelse af D-vitaminanaloger i behandlingen af akne
BG99177A (bg) Нови 7 бета-заместени-4-аза-5 алфа-холестанони като инхибитори на 5 алфа-редуктаза
EA200000506A1 (ru) Состав для снижения веса
DE69711078D1 (de) Topische verwendung von kappa-opioidrezeptoragonisten zur behandlung von augenschmerz
DK0869970T3 (da) Endothelcelleprolifereringsinhibitor og dens anvendelse
FR2700472B1 (fr) Association synergisante ayant un effet antagoniste des récepteurs NK1 et NK2.
ES2116411T3 (es) La sal sulfato de un triazol sustituido, composiciones farmaceuticas de la misma y su uso en terapia
DE69625230D1 (de) Thrombininhibitoren
KR900017595A (ko) 면역억제 방법
ES2171226T3 (es) Composicion para el tratamiento de los lechos para aves de corral.
EP0959899A4 (en) LO-CD2a antibodies and their use to inhibit T-cell activation and proliferation
TR200103748T2 (tr) Organ nakli reddinin inhibe edilmesi için UK 114 proteinin kullanımı
ES2094930T3 (es) Nueva proteina inhibidora de trombina aislada de garrapatas.
ES2148753T3 (es) Sal de metilpirrolidinilindol.